No major difference in protein levels of p110β levels were detected when comparing stage 4 and stages 1–2 neuroblastomas (Figure 1B), although higher levels were seen in MYCN amplified tumors compared to non-amplified tumors (p < 0.05) (Additional file 1). The gene discussed is MYCN; the disease is neuroblastoma.